BPC-157 + TB-500

In a small 56-day phase 2 randomised, double-masked, vehicle-controlled trial in nine patients with severe dry eye, full-length thymosin beta-4 eye drops (RGN-259, 0.1%) reduced ocular discomfort 35.1% more (P = 0.0141) and total corneal fluorescein staining 59.1% more (P = 0.0108) than vehicle at day 56, comparing 12 treated with 6 control eyes.¹⁷

In the only published human report giving both constituents to the same patients, an uncontrolled retrospective chart review of 17 adults with mixed-aetiology knee pain at a single private clinic, 16 of whom were reached by telephone, 3 of the 4 patients given intra-articular BPC-157 with thymosin beta-4 reported significant improvement and 1 reported none, against 11 of 12 after BPC-157 alone; there was no control group, no randomisation and no validated outcome instrument, and the authors used a self-reported pain rating collected from most patients 6 to 12 months after injection.³

In an uncontrolled single-arm pilot study of 12 women with moderate-to-severe interstitial cystitis refractory to pentosan polysulfate, all 12 scored 5 of 5 on the Global Response Assessment after a single procedure delivering BPC-157 around the inflamed bladder wall: 10 of 12 reported complete symptom resolution, 2 of 12 roughly 20% of symptoms persisting. There was no placebo arm, no blinding and no independent replication.¹⁸

A systematic review of 544 records across PubMed, Cochrane and Embase found 36 studies of BPC-157 meeting inclusion criteria, of which 35 were preclinical and 1 was clinical, and characterised the entire body of evidence as level IV and level V, framing every animal result here as hypothesis-generating rather than clinically established.⁶

In rats whose Achilles tendon was transected, intraperitoneal BPC-157 raised load to failure, load to failure per unit area and Young's modulus above saline controls on assessment days 1, 4, 7, 10 and 14, with significantly higher Achilles functional index scores and macroscopic reestablishment of full tendon integrity; three dose arms were run and the report does not resolve the biomechanical outcomes by dose.¹⁹

In rats whose medial collateral ligament was sharply transected and filled with 100 microlitres of fibrin sealant containing 1 microgram of full-length thymosin beta-4, healing tissue at 4 weeks showed evenly spaced collagen fibre bundles, significantly larger collagen fibril diameters, and significantly better biomechanical properties of the femur-ligament-tibia complex than sealant-only controls.²⁰

In rats with surgically induced hind-limb ischaemia, BPC-157 accelerated recovery of blood flow measured by laser Doppler scanning and increased vessel number and vascular VEGFR2 expression in the ischaemic muscle; in cultured human vascular endothelial cells it raised VEGFR2 mRNA and protein without altering VEGF-A.¹⁰

In aged 26-month-old mice with full-thickness dermal wounds, the seven-amino-acid actin-binding fragment LKKTETQ, identified by mass spectrometry as the active ingredient of commercial TB-500, promoted wound repair comparably to the full-length parent peptide; in db/db diabetic mice, full-length thymosin beta-4 significantly increased wound contracture and collagen deposition over controls without changing keratinocyte migration.^1,21

In a rat full-thickness dermal wound model, full-length thymosin beta-4 applied topically or intraperitoneally increased reepithelialisation by 42% over saline controls at 4 days and by as much as 61% at 7 days, with wounds contracting at least 11% more than controls by day 7 and increased collagen deposition and angiogenesis on histology.²²